HMGB1 overexpression was significantly associated with poorer overall survival (HR: 1.99; 95% CI, 1.71–2.31) and progression-free survival (HR: 2.26; 95% CI, 1.65–3.10), irrespective of tumor type, HMGB1 assay procedure (overexpression detected by immunohistochemistry in tissues or ELISA in serum), geographical region and study size. This evidence concerns the gene HMGB1 and neoplasm.